Jennifer Xavier, PhD

Research Assistant Professor

Magee Womens Research Institute 204 Craft Avenue, Room B401
Pittsburgh, PA 15213
Phone: 412-641-7521
Fax: 412-641-2458

Education

BSc (Pharmacology), Newcastle University, United Kingdom (2003)
PhD (Pharmacology), University of Bradford, United Kingdom (2007)
Postdoctoral Fellow, St. Jude Children's Research Hospital, Memphis, TN (2011)
Postdoctoral Fellow, Eli Lilly and Company, Indianapolis, IN (2013)
Jennifer Xavier, PhD

Atkinson JM, Rank K, Capen D, Engler T and Chedid M. Activating the Wnt/b-catenin pathway for the treatment of human melanoma – application of LY2090314, a novel small molecule selective inhibitor of GSK3. PLoS One 10:e0125028, 2015.
Atkinson JM and Gilbertson RJ. Developing treatment strategies for rare cancers. Oncotarget 2:657, 2011.
Atkinson JM, Shelat AA, Carcabosis AM, Kranenburg TA, Arnold LA, Boulos N, Wright KD, Johnson RA, Poppleton H, Mohankumar MM, Feau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung A, Gajjar A, Stewart CF, Guy RK and Gilbertson RJ. An integrated in vitro and in vivo high throughput screen identifies treatment leads for ependymoma. Cancer Cell 20: 384-399, 2011.
Atkinson JM, Falconer RA, Patterson LH, Gill JH and Loadman PM. Development of novel matrix metalloproteinase (MMP) targeted peptide conjugated antivascular agents. Cancer Research 70:6902-6912, 2010.
Johnson R, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Rand V, Leary S, White E, Eden C, Hogg T, Pounds S, Northcott P, Mack S, Neale G, Coyle B, Atkinson JM, DeWire M, Kranenburg TA, Gillespie Y, Allen JC, Merchant T, Boop FA, Sanford RA, Gajjar A, Ellison DW, Taylor MD, Grundy RG and Gilbertson RJ. Cross-species genomics matches driver mutations and cell compartments to model Ependymoma. Nature 466:632-636, 2010.